Anti-Human CD8 [Clone UCHT-4] — Purified in vivo GOLD™ Functional Grade

Clone UCHT-4 is a monoclonal antibody directed against human CD8 and is mainly used in immunology research, including in vivo mouse studies, for applications involving T-cell identification, depletion, and functional modulation.

In in vivo mouse experiments, UCHT-4 is typically employed in the following ways:

• Depletion of human CD8+ T cells: UCHT-4 can be administered to mice engrafted with a human immune system (such as humanized mouse models) to selectively remove CD8+ T cells, thereby enabling the study of their role in immune responses, tumor immunity, or infectious diseases.
• Phenotypic or functional analysis: The antibody can help investigate the function and influence of human CD8+ T cells within the mouse model, for example, by analyzing outcomes when these cells are absent or inhibited due to antibody treatment.

Since UCHT-4 is specific for human CD8, it is mainly relevant in mouse models that possess a humanized immune system (for example, after engraftment with human hematopoietic stem cells or PBMCs), not in wild-type mice.

Supporting context:

• UCHT-4 is valuable in T-cell research, oncology, and infectious disease by enabling the specific targeting of human CD8+ cells in the context of a functioning (humanized) immune system in mice.
• The depletion or inhibition strategy allows researchers to dissect the specific contributions of CD8+ T cells to various immune phenomena in in vivo settings.

There is no evidence from the provided search results suggesting that UCHT-4 cross-reacts with murine CD8, so its use is focused solely on humanized models.

If you require experimental protocol details (such as dosing, administration routes, or in vivo efficacy data), these specifics are not present in the retrieved documents and would need to be sourced from primary literature or product datasheets.

Commonly used antibodies or proteins alongside UCHT-4 in the literature are typically those targeting related epitopes or proteins within the same experimental context, such as other monoclonal antibodies targeting regions of interest (e.g., HIV Env, Tau protein, cell markers) or proteins relevant for detection and functional assays.

Essential context and details:

• Cocktail approaches: In HIV research, combinations of monoclonal antibodies such as A32 (anti-cluster A), 17b (anti-CoRBS), 246D (anti-gp41 cluster I), and CD4-mimetic compounds like CJF-III-288 are commonly used together to study antibody-dependent cellular cytotoxicity (ADCC) and recognition of infected cells. These combinations can be more effective than using individual antibodies alone.
• Control antibodies: When developing or testing new antibodies for detection or functional analysis, researchers often use controls such as isotype control antibodies (that do not bind the antigen in question) or antibodies against unrelated epitope tags or peptides (e.g., nonspecific peptide antigen CXCR5 when testing anti-SMAD2 antibody specificity).
• Detection and enzyme conjugates: For assays like ELISA and Western blotting, enzyme-conjugated secondary antibodies (e.g., sheep anti-mouse IgG-HRP, donkey anti-rabbit IgG-HRP) are widely used for detection. The enzymes most frequently conjugated to these antibodies include horseradish peroxidase (HRP) and alkaline phosphatase (AP).
• Functional partners for pairing: In studies requiring recombinant antibody synthesis or sequencing, mixtures of heavy and light chain antibodies are paired to reconstitute functional antibodies, and multiple combinations may be tested in parallel.
• Experimental validation panels: In disease biomarker research, large panels of antibodies targeting related proteins (e.g., 79 distinct anti-Tau antibodies for neurodegenerative research, as listed in antibody databases like Benchsci, Antibodypedia, and Alzforum) are validated for detection in techniques such as Western blot and immunohistochemistry.

Additional notes:

• The precise antibodies or proteins used with UCHT-4 depend heavily on the experimental goal—whether it is flow cytometry, biochemical assays, antibody-dependent cellular cytotoxicity (ADCC) studies, or detection of specific cell surface markers.
• Controls and detection reagents (e.g., secondary antibodies, enzymes) are essential in most protocols for specificity and sensitivity.
• When applying cocktails or panels (combining multiple antibodies), the chosen antibodies typically target non-overlapping or complementary epitopes to enhance sensitivity or functional outcomes.

Key Findings from clone UCHT-4 Citations in Scientific Literature

Clone UCHT-4 is a monoclonal antibody clone specific for human CD8, a marker predominantly expressed on cytotoxic T cells and some regulatory T cell subsets. While the provided search results include a product datasheet for anti-CD8-Quantum Red, clone UCHT-4, there is no direct mention of specific scientific findings from primary research publications using this clone in the presented excerpts. However, the datasheet lists several references that are likely to include original research articles where UCHT-4 was employed as a reagent for T cell characterization. Below is a synthesis of expected and indicative findings based on the scientific context and the types of studies typically cited for such reagents.

Indicative Research Context for UCHT-4

• CD8 as a T Cell Marker: Clone UCHT-4 is frequently used in cytometry and immunoassays to identify and characterize CD8+ T cells in human samples. This is fundamental in immunology for distinguishing cytotoxic T cells from other lymphocyte populations.
• Hybridoma Development: The clone was generated by fusion of a mouse myeloma cell line with splenocytes from Balb/c mice immunized with human thymocytes and peripheral blood T cells, indicating its specificity for human CD8.
• Fluorochrome Conjugates: The datasheet describes a Quantum Red conjugate (a tandem dye combining R-Phycoerythrin and Cy5), highlighting its use in multicolor flow cytometry applications where spectral overlap must be minimized.

Typical Findings from Original Citations

Although detailed content from the specific citations is not provided in the search results, the references listed in the datasheet are classic papers in immunology and lymphocyte phenotyping. You can reasonably expect the following types of findings from such citations:

• Discovery and Characterization of CD8+ Subsets: Early work using UCHT-4 helped define the surface phenotype of CD8+ T cells and their roles in immune responses.
• Functional Studies: Research likely includes investigations into the activation, proliferation, and effector functions of CD8+ T cells identified by UCHT-4.
• Clinical Correlates: Studies may link CD8+ T cell subsets (stained with UCHT-4) with disease states, such as viral infections, cancer, and autoimmune disorders.

Limitations of Available Information

The search results do not provide direct access to the full texts of the cited papers or detailed summaries of their findings. Therefore, the above points are based on the expected scientific content associated with such a well-established immunological reagent and the context provided by the datasheet.

Summary Table

Conclusion

Clone UCHT-4 is a critical tool in immunology for identifying human CD8+ T cells. While the search results do not detail specific experimental results from the original citations, these papers are foundational in establishing the use of UCHT-4 for phenotyping, functional analysis, and clinical correlation studies of CD8+ T cell populations in health and disease. For precise scientific findings, direct examination of the individual cited works (e.g., Reinherz et al., 1980, 1981; Merkenschlager et al., 1988, 1989; Martin et al., 1984; etc.) would be required.

The dosing regimens of clone UCHT-4 (an anti-human CD3 monoclonal antibody) are not explicitly detailed in the provided search results. No direct information was found regarding UCHT-4 regimens in mouse models.

However, here is essential context and practice inferred from general antibody dosing strategies, which are pertinent for mouse models using anti-CD3 or similar depleting antibodies:

• Antibody dosing in mice typically ranges between 100–250 ?g per mouse, most often delivered via intraperitoneal injection.
• The dose frequency is usually every 3–4 days or 2–3 times per week, depending on the application, desired depletion, or immune modulation.
• Dosing regimens can vary depending on the specific mouse model, target tissue, desired degree of T cell depletion, and experimental goals. Larger or immune-privileged sites, aggressive tumors, or chronic infection models may require modified (more frequent or higher) dosing regimens.

If you are seeking information specifically on clone UCHT-4:

• It is primarily a human T cell–specific antibody (rat anti-human CD3, IgG1), so use in mouse models generally requires humanized mice expressing human CD3 or engrafted with human immune cells.
• The regimen for humanized antibodies and models closely follows the principles above but must be tailored according to the pharmacokinetics in the specific mouse model, as the half-life and clearance can differ substantially between breeds and mouse-human chimeras.

Summary Table: (General Guide Based on Anti-T Cell Antibody Use in Mice)

Key variables for UCHT-4:

• Dose is often determined empirically in pilot studies to match intended depletion.
• Must use in models with human CD3-expressing cells for efficacy.
• Split dosing or more frequent scheduling may be needed if the antibody has a short half-life or rapid clearance, as is common in murine hosts.

If you require explicit published regimens for clone UCHT-4, consulting targeted literature or manufacturer datasheets for UCHT-4 in humanized mouse models is recommended. No direct regimens for UCHT-4 were found in the provided search results.